Obesity: Roche with first clinical data after US$2.7bn deal
Following the acquisition of Carmot Therapeutics in December 2023 for US$2.7bn biobucks (US$400m upfront), Roche has now announced the results of...
Gut bacteria seed autoimmunity-inducers
A unique mechanism, reported by an Irish-French research team underscores an emerging theme in microbiome research: that disruptions to gut bacteria...
Consortium led by Evotec enters obesity drug space
The newly formed strategic partnership between Evotec SE, Inserm, Lille University Hospital and Inserm Transfert aims to identify novel multimodal...
Biotalys starts field testing for biofungicide
The protein-based biofungicide is under development of the company’s Agrobody technology platform for sustainable biocontrols as an alternative...
Forbion closes first Bioeconomy Fund with US$75m
Life Science investor Forbion opens a new sector for its lead partners who were eager to put money into industries within the ESG standards. At...
Tacalyx' extends seed capital financing
Tacalyx GmbH, the 2019 spin-out from Peter Seeberger's glycan research group, has doubled its seed funding from €7m to to a bit over €14m to advance...
Ipsen puts US$1.8bn in pipeline expansion in movement disorders
Under the agreement, Skyhawk will provide its discovery platform for RNA-targeting small molecules across several therapeutic areas, including rare...